Hot
Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein, His Tag&Tag Free, low endotoxinCat. No. IT1-H52W5
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Integrin alpha 5 beta 1 | HOT IT1-H52W5 | Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein, His Tag&Tag Free, low endotoxin | Human | HEK293 | ![]() | SDS-PAGE | $485.00 100ug | ||
| Integrin alpha 5 beta 1 | Cynomolgus Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein, His Tag&Tag Free (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $485.00 100ug | |||
| Integrin alpha 5 beta 1 | Avitag IT1-H82Wa | Biotinylated Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Risuteganib | ALG-1001; AM011; AM-011(Allegro Ophthalmics) | Phase 1 Clinical | Allegro Ophthalmics Llc | Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration | Details |
| Pegylated recombinant human endostatin (Tsinghua University) | M-2ES; CRB-0401 | Phase 1 Clinical | Beijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua University | Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| VAX-014 | VAX-014 | Phase 1 Clinical | Vaxiion Therapeutics Llc | Solid tumours | Details |
| Integrin α5β1 therapy (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Cardiovascular Diseases | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human endostatin (Simcere) | YH-16 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Endostar, 恩度, Endu | Mainland China | Carcinoma, Non-Small-Cell Lung | Shandong Xiansheng Zaiming Biopharmaceutical Co Ltd | 2005-09-12 | Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant | Details |